Study acronym | Study group | Baseline CRP (mg/L) | CRP inclusion criteria | |
IMPACT 211 | Infliximab | Mean 19 | SD 24 | Either CRP ≥15 mg/L and/or morning stiffness ≥45 min |
Placebo | Mean 23 | SD 34 | ||
GO-REVEAL13 | Golimumab 50 mg | Mean 13 | SD 16 | / |
Golimumab 100 mg | Mean 14 | SD 18 | ||
Placebo | Mean 13 | SD 16 | ||
ADEPT14 | Adalimumab | Mean 14 | SD 21 | / |
Placebo | Mean 14 | SD 17 | ||
SPIRIT-P116 | Adalimumab | Mean 13.2 | SD 19.1 | Either ≥1 PsA-related hand or foot joint erosion on centrally read X-rays or CRP >6 mg/L |
Ixekizumab every 2 weeks | Mean 15.1 | SD 25.9 | ||
Ixekizumab every 4 weeks | Mean 12.8 | SD 16.4 | ||
Placebo | Mean 15.1 | SD 23.6 | ||
OPAL BROADEN17 | Tofacitinib 5 mg | Median 4.8 | Range 0.2–115 | / |
Tofacitinib 10 mg | Median 5.1 | Range 0.2–92.9 | ||
Adalimumab | Median 4.3 | Range 0.2–131.0 | ||
Placebo | Median 5.0 | Range 0.2–113.0 | ||
RAPID-PsA19 | Certolizumab every 2 weeks | Median 7.0 | Min 0.2 – Max 238.0 | Either ESR ≥28 mm/hour or CRP >7.9 mg/L |
Certolizumab every 4 weeks | Median 8.7 | Min 0.1 – Max 131.0 | ||
PSUMMIT 126 | Ustekinumab 45 mg | Median 10.0 | IQR 5.9–21.1 | CRP ≥3 mg/L |
Ustekinumab 90 mg | Median 12.3 | IQR 6.5–21.7 | ||
Placebo | Median 9.6 | IQR 6.0–18.6 | ||
PSUMMIT 228 | Ustekinumab 45 mg | Median 13.0 | IQR 4.5–36.3 | Screening CRP ≥6 mg/L, modified to ≥3 mg/L after study start |
Ustekinumab 90 mg | Median 10.1 | IQR 4.8–19.8 | ||
Placebo | Median 8.5 | IQR 4.6–22.0 | ||
DISCOVER 129 | Guselkumab every 4 weeks | Median 6 | IQR 3–13 | CRP ≥3 mg/L |
Guselkumab every 8 weeks | Median 7 | IQR 4–19 | ||
Placebo | Median 8 | IQR 3–15 | ||
DISCOVER 230 | Guselkumab every 4 weeks | Median 12 | IQR 6–23 | CRP ≥6 mg/L |
Guselkumab every 8 weeks | Median 13 | IQR 7–25 | ||
Placebo | Median 12 | IQR 2–26 | ||
ASTRAEA31 | Abatacept | Mean 14.0 | SD 20.9 | / |
Placebo | Mean 14.3 | SD 30.3 | ||
OPAL BEYOND33 | Tofacitinib 5 mg | Median 5.7 | Range 0.2–126.0 | / |
Tofacitinib 10 mg | Median 4.9 | Range 0.2–163.0 | ||
Placebo | Median 4.4 | Range 0.2–164.0 | ||
PALACE 134 | Apremilast 20 mg | Mean 9.0 | SD 14.09 | / |
Apremilast 30 mg | Mean 8.4 | SD 10.24 | ||
Placebo | Mean 11 | SD 14.36 | ||
PALACE 336 | Apremilast 20 mg | Mean 9.7 | SD 15.1 | / |
Apremilast 30 mg | Mean 11.5 | SD 18.8 | ||
Placebo | Mean 10 | SD 13.5 | ||
PALACE 437 | Apremilast 20 mg | Mean 9 | SD 11 | / |
Apremilast 30 mg | Mean 8 | SD 11 | ||
Placebo | Mean 11 | SD 27 | ||
ACTIVE38 | Apremilast 30 mg | Mean 14.4 | SD 16 | CRP ≥2 mg/L |
Placebo | Mean 12.5 | SD16 |
CRP, C reactive protein; ESR, erythrocyte sedimentation rate; max, maximum; PsA, psoriatic arthritis.